Dr Reddy's Laboratories Total Long-Term Assets 2010-2024 | RDY
Dr Reddy's Laboratories total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
- Dr Reddy's Laboratories total long-term assets for the quarter ending September 30, 2024 were $2.601B, a 67.16% increase year-over-year.
- Dr Reddy's Laboratories total long-term assets for 2024 were $1.674B, a 19.66% increase from 2023.
- Dr Reddy's Laboratories total long-term assets for 2023 were $1.399B, a 4.31% decline from 2022.
- Dr Reddy's Laboratories total long-term assets for 2022 were $1.462B, a 8.74% decline from 2021.
Dr Reddy's Laboratories Annual Total Long-Term Assets
(Millions of US $) |
| 2024 |
$1,674 |
| 2023 |
$1,399 |
| 2022 |
$1,462 |
| 2021 |
$1,602 |
| 2020 |
$1,351 |
| 2019 |
$1,605 |
| 2018 |
$1,782 |
| 2017 |
$1,842 |
| 2016 |
$1,328 |
| 2015 |
$1,202 |
| 2014 |
$1,107 |
| 2013 |
$1,041 |
| 2012 |
$973 |
| 2011 |
$1,064 |
| 2010 |
$851 |
| 2009 |
$470 |
Dr Reddy's Laboratories Quarterly Total Long-Term Assets
(Millions of US $) |
| 2024-09-30 |
$2,601 |
| 2024-06-30 |
$1,754 |
| 2024-03-31 |
$1,674 |
| 2023-12-31 |
$1,616 |
| 2023-09-30 |
$1,556 |
| 2023-06-30 |
$1,521 |
| 2023-03-31 |
$1,399 |
| 2022-12-31 |
$1,388 |
| 2022-09-30 |
$1,417 |
| 2022-06-30 |
$1,472 |
| 2022-03-31 |
$1,462 |
| 2021-12-31 |
$1,556 |
| 2021-09-30 |
$1,556 |
| 2021-06-30 |
$1,607 |
| 2021-03-31 |
$1,602 |
| 2020-12-31 |
$1,628 |
| 2020-09-30 |
$1,609 |
| 2020-06-30 |
$1,561 |
| 2020-03-31 |
$1,351 |
| 2019-12-31 |
$1,411 |
| 2019-09-30 |
$1,612 |
| 2019-06-30 |
$1,618 |
| 2019-03-31 |
$1,605 |
| 2018-12-31 |
$1,637 |
| 2018-09-30 |
$1,636 |
| 2018-06-30 |
$1,693 |
| 2018-03-31 |
$1,782 |
| 2017-12-31 |
$1,825 |
| 2017-09-30 |
$1,822 |
| 2017-06-30 |
$1,832 |
| 2017-03-31 |
$1,842 |
| 2016-12-31 |
$1,794 |
| 2016-09-30 |
$1,806 |
| 2016-06-30 |
$1,386 |
| 2016-03-31 |
$1,328 |
| 2015-12-31 |
$1,337 |
| 2015-09-30 |
$1,317 |
| 2015-06-30 |
$1,341 |
| 2015-03-31 |
$1,684 |
| 2014-12-31 |
$394 |
| 2014-09-30 |
$360 |
| 2014-06-30 |
$372 |
| 2014-03-31 |
$367 |
| 2013-12-31 |
$361 |
| 2013-09-30 |
$343 |
| 2013-06-30 |
$332 |
| 2013-03-31 |
$347 |
| 2012-12-31 |
$328 |
| 2012-09-30 |
$311 |
| 2012-06-30 |
$313 |
| 2012-03-31 |
$320 |
| 2011-12-31 |
$342 |
| 2011-09-30 |
$397 |
| 2011-06-30 |
$424 |
| 2011-03-31 |
$398 |
| 2010-12-31 |
$349 |
| 2010-09-30 |
$338 |
| 2010-06-30 |
$334 |
| 2010-03-31 |
$351 |
| 2009-12-31 |
$299 |
| 2009-09-30 |
$489 |
| 2009-06-30 |
$498 |
| 2009-03-31 |
$470 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$11.677B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
